Washington DC
New York
Toronto
Distribution: (800) 510 0384
Press ID
  • Login
Fairmont Post
No Result
View All Result
Sunday, June 8, 2025
  • Business • Financial
  • Culture • Entertainment
  • Lifestyle • Travel
  • Technology • Science
  • Environment • Conservation
  • FinTech • Blockchain NFT
  • Business • Financial
  • Culture • Entertainment
  • Lifestyle • Travel
  • Technology • Science
  • Environment • Conservation
  • FinTech • Blockchain NFT
No Result
View All Result
Fairmont Post
No Result
View All Result

Novel Regeneron Bispecific Antibodies Show Encouraging Anti-Tumor Activity in Two Advanced Solid Tumors

First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer

Eva Semel by Eva Semel
September 11, 2022
in Science
A A
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive early data for two novel and investigational bispecific antibodies – ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer (NSCLC). The initial safety and efficacy results are from the dose-escalation portions of two Phase 1/2 trials and are being presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.

“Bispecific antibodies are an important component of our oncology pipeline because of their flexibility to potentially address a variety of cancers,” said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. “At ESMO, we’re showcasing this flexibility with ubamatamab and REGN5093, two novel bispecific antibodies that are initially being investigated as monotherapies for recurrent ovarian cancer and MET-altered advanced lung cancer, respectively. They were among the first in our pipeline to progress into clinical trials for solid tumors, and we’re encouraged to see both showing anti-tumor activity in dose escalation. These first-in-class results give us confidence in our VelociBi® bispecific development platform, and we look forward to investigating ubamatamab and REGN5093 further.”

READ ALSO

Vialox Peptide: Speculative Research Potential

Isam Vaid on Shaping Future Leaders

As shared in a mini-oral at ESMO, ubamatamab is a CD3-targeting bispecific under investigation for recurrent ovarian cancer and designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation. Dose-escalation results were presented for 78 patients with recurrent ovarian cancer who had received a median of 4.5 prior treatments, including platinum-based chemotherapy and a median duration of exposure to ubamatamab was 12 weeks (range: <1 to 145 weeks).Within 42 patients who received ≥1 full doses of ≥20 mg ubamatamab, a 14% (6 of 42 patients) overall response rate (ORR) was achieved across dose levels. The ORR increased to 21% (6 of 29 patients) in those without visceral metastases (exploratory subset) and 31% (4 of 13 patients) in those with high MUC16-expressing tumors (preliminary exploratory subset). Across dose levels, the disease control rate was 57% (24 of 42 patients), and the median duration of response was 12 months per Kaplan-Meier estimates (range: 4 to ≥24 months). Safety was assessed in 78 ubamatamab-treated patients, with the most common adverse events (AEs) in ≥15% being cytokine release syndrome (74%, all ≤grade 2), pain (87%) and anemia (51%). AEs that were ≥grade 3 occurred in 65% of patients with those in >5% including anemia (24%), pain (23%) and neutropenia (8%). There was one instance of a dose-limiting toxicity (neutropenia) and three deaths due to AEs, none of which were considered related to treatment by sponsor assessment. Based on these efficacy and safety data, the Phase 2 portion of the trial is enrolling patients with platinum-resistant ovarian cancer to further investigate ubamatamab as a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab).

Preliminary first-in-human results for REGN5093 were also published in an ESMO scientific abstract, with updated data and additional response rates to be detailed in a poster session on Monday, September 12. REGN5093 is a tumor-targeting bispecific designed to bind to the MET receptor in two places and trigger rapid internalization of this complex into cancer cells to degrade the MET receptor and block its ability to support cell proliferation. As highlighted in the abstract, among 36 patients with MET-altered advanced NSCLC who received the highest dose tested to date, 6 experienced a partial response with 5 of these responses occurring in patients who had received prior anti-PD-1 treatment. Total exposure to treatment was approximately 467 patient-weeks.

AEs that were ≥grade 3 occurred in 25% (n=11) of REGN5093-treated patients, with pneumonia and pulmonary embolism each occurring in 2 patients. One patient discontinued treatment due to increased alanine aminotransferase and aspartate aminotransferase. No dose-limiting toxicities or treatment-related deaths have been observed as of data cutoff. These early efficacy and safety data support further dose expansions, and a separate Phase 1/2 trial is ongoing to investigate an antibody-drug conjugate format of REGN5093 (REGN5093-M114).

The potential uses of ubamatamab, Libtayo, REGN5093 and REGN5093-M114 described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

FP Newsroom

Vialox Peptide: Speculative Research Potential
Science

Vialox Peptide: Speculative Research Potential

May 29, 2025
Isam Vaid on Shaping Future Leaders
Science

Isam Vaid on Shaping Future Leaders

April 21, 2025
Formerra to Showcase Solutions for Medical Device Manufacturers at MD&M West
Science

Formerra to Showcase Solutions for Medical Device Manufacturers at MD&M West

February 2, 2025
How XTEND OPTIMAL HEALTH Works With V Cells and Stem Cells
Science

How XTEND OPTIMAL HEALTH Works With V Cells and Stem Cells

November 20, 2024
Science

ClearPoint Neuro’s SmartFlow Cannula Receives FDA Approval for Gene Therapy Delivery in AADC Deficiency

November 16, 2024
Tonix Pharmaceuticals Developing Vaccine Candidate to Combat Mpox Crisis and Potential Future Pandemics
Science

Tonix Pharmaceuticals Developing Vaccine Candidate to Combat Mpox Crisis and Potential Future Pandemics

August 23, 2024

News in Focus

From Mumbai to Los Angeles: Cinematographer Eeshan Kamath’s Rise as a Visionary Talent

Vincenzo Carnovale Elaborates on Why Food is the Ultimate Connector of People and Cultures

Hogan Brooks: Leaving A Legacy of Hard Work and Virtue

Breaking the Stigma: Managing Mental Health With Chronic Conditions

The Love Odyssey: Navigating Relationships With Self-Love and Vulnerability

PG&E and Smart Wires Collaborate on Innovative Grid Enhancement Project in San Jose, CA

Data-Driven Decision-Making: How Businesses Can Improve Strategic Planning With Analytics

Ambassador William E. Grayson Named Commissioner General for USA Pavilion at Expo 2025 Osaka

Creating a Data-Driven Culture in Mission-Driven Organizations

Neutral’s Groundbreaking Ceremony Marks Milestone for Sustainable Living in Milwaukee

BK8: An Inspiration of Charitable Giving and Social Responsibility in Sports

Vialox Peptide: Speculative Research Potential

U.S. Eases Sanctions on Syria With New General License, Aiming for Economic Recovery and Stability

Golden Coast Beach Hotel: An Easy Escape to Protaras That Actually Feels Like a Break

From Struggle to Strength: How Avidator is Empowering UK Students to Master Maths and Build Academic Confidence

Optimizing Modern Data Ingestion Techniques With Tips From Nathaniel DiRenzo

Executives Are Rewiring Public Speaking Anxiety With This Science-Based Method

How to Become a Professional Trader and Investor: Lessons From Corrado Garibaldi

Sustainability Partners Takes Helm of Daily Operations for Ecofin U.S. Renewables Infrastructure Trust

Overcoming Entrepreneurial Burnout: Dustin Pillonato’s Tips for Maintaining Balance

Virtual Public Speaking: Thriving in the Era of Online Presentations

From Outreach to Impact: Designing Community Health Programs That Work

Unlocking Real Estate Success: Allan Polendey’s Course on Foreclosure Investments to Launch This Summer

Federal Law Enforcement Officers Association (FLEOA) to Participate in Police Week 2025 Events and Advocacy Efforts on Capitol Hill

Even the Helicopter Matters: Why the 1% Deserve Compassionate, Competent Mental Health Care

Jeff Hawks: Optimizing In-House Supply Chain Systems

Leading With Vision: Nicksain Kalaimathian’s Innovations in the Tech Industry

Experience Language and Culture With DIALOG Sprachreisen

Loa77: Spain’s Award-Winning Organic Extra Virgin Olive Oil Now Available in the USA

Rebuilding Self-Confidence After a Toxic Relationship: Practical Strategies for Emotional Growth

  • Kia America представляет цены и захватывающие обновления для Sorento 2025 (ICE)

https://madisongraph.com/kia-america-unveils-pricing-and-exciting-updates-for-2025-sorento-ice/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • Kia Recognized as One of TIME Magazine’s “World’s Most Sustainable Companies of 2024”

https://madisongraph.com/kia-recognized-as-one-of-time-magazines-worlds-most-sustainable-companies-of-2024/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • VinFast Auto Establishes Dealer Advisory Board to Enhance Customer Experience

https://madisongraph.com/vinfast-auto-establishes-dealer-advisory-board-to-enhance-customer-experience/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • Medicare Announces Expansion of Coverage for Microprocessor-Controlled Knees for Lower Mobility Users

https://lincolncitizen.com/medicare-announces-expansion-of-coverage-for-microprocessor-controlled-knees-for-lower-mobility-users/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • GA-ASI Successfully Tests PT6 Engine on MQ-9B SkyGuardian Aircraft

https://lincolncitizen.com/ga-asi-successfully-tests-pt6-engine-on-mq-9b-skyguardian-aircraft/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • U.S. Leading Economic Index Declines by 0.2% in June 2024, Coincident Index Rises by 0.3%

https://fairmontpost.com/u-s-leading-economic-index-declines-by-0-2-in-june-2024-coincident-index-rises-by-0-3/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • USTDA Director Travels to Bulgaria and Romania to Promote Clean, Secure Energy

https://belmontstar.com/ustda-director-travels-to-bulgaria-and-romania-to-promote-clean-secure-energy/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • Police Recommend a Hidden Camera Detector Device to Protect Privacy

https://marketsherald.com/police-recommend-a-hidden-camera-detector-device-to-protect-privacy/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost

© 2025 Fairmont Post. Published by The Ritz Herald. Editions: Markets Herald • Lincoln Citizen • Madison Graph • Belmont Star • The Hudson Weekly

Address: 1177 6th Avenue, 5th Floor, New York, NY 10036. Removals: pr@fairmontpost.com. Phone: (718) 313-5252. Mon-Fri: 9AM-5PM. Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Business • Financial
  • Culture • Entertainment
  • Lifestyle • Travel
  • Technology • Science
  • Environment • Conservation
  • FinTech • Blockchain NFT

© 2025 Fairmont Post